Campbell R W, Furniss S S
Academic Cardiology Unit, Freeman Hospital, Newcastle upon Tyne, England.
Am J Cardiol. 1993 Aug 12;72(4):80A-85A. doi: 10.1016/0002-9149(93)90029-c.
Sotalol is a unique antiarrhythmic drug that combines beta-blocking effects with actions to prolong action potential duration. The net effect is a drug that is efficacious in the management of ventricular tachyarrhythmias. Although sotalol has effects on both heart rate and QT interval, these effects do not help predict the antiarrhythmic efficacy of the agent. Changes in QT dispersion may, however, prove to be relevant to both the antiarrhythmic effects and the arrhythmogenic effects of sotalol. Thus, although sotalol may occasionally cause torsades de pointes, this complication may be predictable and clinically controllable. Sotalol is well tolerated, and it may be used, with caution, in some patients with impaired myocardial contractile performance, despite its beta-blocking action. Sotalol has an important indication for the management of ventricular tachyarrhythmias.
索他洛尔是一种独特的抗心律失常药物,它兼具β受体阻滞作用和延长动作电位时程的作用。其综合效应是一种对室性快速性心律失常治疗有效的药物。尽管索他洛尔对心率和QT间期均有影响,但这些影响无助于预测该药物的抗心律失常疗效。然而,QT离散度的变化可能与索他洛尔的抗心律失常作用和致心律失常作用均相关。因此,尽管索他洛尔偶尔可能会引起尖端扭转型室速,但这种并发症可能是可预测且临床可控的。索他洛尔耐受性良好,尽管有β受体阻滞作用,但在一些心肌收缩功能受损的患者中,可谨慎使用。索他洛尔在室性快速性心律失常的治疗中具有重要的适应证。